drugset / Trial / NCT07190833
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Non-randomizedSequentialOpen-labelTreatment
Summary
This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of cancer.
Timeline
- Start
- 2026-03-09
- Primary completion
- 2028-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Hydroxyurea | Other / unclassified | 15 mg/kg | Oral |
| Subject | Hydroxyurea | Other / unclassified | 25 mg/kg | Oral |
| Subject | Hydroxyurea | Other / unclassified | 35 mg/kg | Oral |
| Subject | OTS-412 | Unknown | 1e+08 unknown | Intrathecal |
| Subject | OTS-412 | Unknown | 3e+08 unknown | Intrathecal |